Public Health

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.

In a placebo-controlled, randomized trial, researchers tested the efficacy of cytisinicline—a smoking cessation medication—for those who would like to quit smoking.

In a retrospective cohort study, researchers investigated the treatment patterns for adults in the United States with alopecia areata from 2015 to 2020.

In a double-blinded, randomized study, a team of researchers evaluated the safety and efficacy of the use of toothpaste containing hydroxyapatite.

Findings show that children in early childhood are not completing their multidose vaccine series due to some structural barriers.

The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.

The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.

Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.